| The Amyloid-beta Oligomer Hypothesis: Beginning of the Third Decade |
102 |
| Mitochondria and Mitochondrial Cascades in Alzheimer's Disease |
80 |
| Gut Microbiota is Altered in Patients with Alzheimer's Disease |
74 |
| Religious Orders Study and Rush Memory and Aging Project |
73 |
| Amsterdam Dementia Cohort: Performing Research to Optimize Care |
39 |
| Protective Effects of Indian Spice Curcumin Against Amyloid-beta in Alzheimer's Disease |
39 |
| Oxidative Stress, Amyloid-beta Peptide, and Altered Key Molecular Pathways in the Pathogenesis and Progression of Alzheimer's Disease |
38 |
| Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options |
37 |
| Alzheimer's Amyloid-beta is an Antimicrobial Peptide: A Review of the Evidence |
34 |
| Different Cognitive Frailty Models and Health- and Cognitive-related Outcomes in Older Age: From Epidemiology to Prevention |
33 |
| Metformin Use Associated with Reduced Risk of Dementia in Patients with Diabetes: A Systematic Review and Meta-Analysis |
32 |
| Iron and Alzheimer's Disease: An Update on Emerging Mechanisms |
31 |
| Metals and Alzheimer's Disease: How Far Have We Come in the Clinic? |
30 |
| The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review |
29 |
| A Long Journey into Aging, Brain Aging, and Alzheimer's Disease Following the Oxidative Stress Tracks |
27 |
| Assay of Plasma Phosphorylated Tau Protein (Threonine 181) and Total Tau Protein in Early-Stage Alzheimer's Disease |
27 |
| Air Pollution and Dementia: A Systematic Review |
27 |
| Differences Between Women and Men in Incidence Rates of Dementia and Alzheimer's Disease |
27 |
| Alzheimer's Disease, Oligomers, and Inflammation |
27 |
| Multivariate Approach for Alzheimer's Disease Detection Using Stationary Wavelet Entropy and Predator-Prey Particle Swarm Optimization |
26 |
| Plasma Amyloid-beta (A beta(42)) Correlates with Cerebrospinal Fluid A beta(42) in Alzheimer's Disease |
26 |
| Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology |
23 |
| Alzheimer's Disease: Recent Concepts on the Relation of Mitochondrial Disturbances, Excitotoxicity, Neuroinflammation, and Kynurenines |
23 |
| Air Pollution, Stress, and Allostatic Load: Linking Systemic and Central Nervous System Impacts |
23 |
| Memantine for the Treatment of Dementia: A Review on its Current and Future Applications |
22 |
| Metformin Improves Learning and Memory in the SAMP8 Mouse Model of Alzheimer's Disease |
21 |
| The Role of the Gut Microbiota in the Metabolism of Polyphenols as Characterized by Gnotobiotic Mice |
21 |
| Alzheimer's Disease: A Journey (f)rom Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies |
21 |
| The Past and the Future of Alzheimer's Disease Fluid Biomarkers |
21 |
| Mesenchymal Stem Cell-Derived Extracellular Vesicles Suppresses iNOS Expression and Ameliorates Neural Impairment in Alzheimer's Disease Mice |
21 |
| Role of Blood-Brain Barrier in Alzheimer's Disease |
20 |
| Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial |
20 |
| Ketogenic Medium Chain Triglycerides Increase Brain Energy Metabolism in Alzheimer's Disease |
20 |
| Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Progress and Potential Pitfalls |
20 |
| The Association between Social Engagement, Loneliness, and Risk of Dementia: A Systematic Review and Meta-Analysis |
20 |
| Social Isolation and Cognitive Function in Later Life: A Systematic Review and Meta-Analysis |
20 |
| Tau Proteolysis in the Pathogenesis of Tauopathies: Neurotoxic Fragments and Novel Biomarkers |
19 |
| Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer's Disease and Related Dementias and Strategic Implications for Stakeholders |
19 |
| Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future |
19 |
| A Decade of Blood Biomarkers for Alzheimer's Disease Research: An Evolving Field, Improving Study Designs, and the Challenge of Replication |
18 |
| The Conundrum of GSK3 Inhibitors: Is it the Dawn of a New Beginning? |
18 |
| Multifactorial Hypothesis and Multi-Targets for Alzheimer's Disease |
17 |
| Molecular Mechanisms and Genetics of Oxidative Stress in Alzheimer's Disease |
17 |
| The Vascular Hypothesis of Alzheimer's Disease: A Key to Preclinical Prediction of Dementia Using Neuroimaging |
17 |
| Linking Atrial Fibrillation with Alzheimer's Disease: Epidemiological, Pathological, and Mechanistic Evidence |
16 |
| Tau Biology, Tauopathy, Traumatic Brain Injury, and Diagnostic Challenges |
16 |
| Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions |
16 |
| Update on Vascular Cognitive Impairment Associated with Subcortical Small-Vessel Disease |
16 |
| Assessing Mild Behavioral Impairment with the Mild Behavioral Impairment-Checklist in People with Mild Cognitive Impairment |
16 |
| Abnormalities of Resting State Cortical EEG Rhythms in Subjects with Mild Cognitive Impairment Due to Alzheimer's and Lewy Body Diseases |
16 |
